Kennedy Jr.-Backed Peptide Used Despite Lacking Data

An experimental peptide known as BPC-157, which has gained traction online for purported benefits in pain relief, healing, and performance enhancement, is being used for a broad spectrum of ailments. This usage occurs despite a significant lack of safety and efficacy evidence derived from human studies, according to a recent analysis. The peptide has not received approval in the United States but has found a consumer base in a gray market, partly fueled by social media testimonials promoting benefits for muscle growth and injury recovery that lack scientific backing.

The U.S. Food and Drug Administration's panel voted in July to allow compounding of BPC-157, a move encouraged by Robert F. Kennedy Jr. Previously, the FDA had restricted its compounding due to safety concerns and insufficient human data. Analysts estimate that BPC-157 and similar peptides could represent a $2 billion to $3 billion market if legitimized.

Data analytics firm nference reviewed over 15 million medical records, identifying 1,039 patients whose doctors had documented BPC-157 use in written clinical notes, as electronic records lack a National Drug Code for the peptide. The number of new confirmed users surged 33-fold between 2020 and 2026. Documented reasons for use in 644 patients included sports injuries, chronic pain, and gastrointestinal disorders, often initiated for pain or digestive symptoms.

Demographic shifts show an increase in male users, from 57% in 2020 to 70% in 2026, while the average age decreased from 55 to 49. The majority of users (96%) were white. Treatment responses were recorded for only a third of patients, with some notes indicating symptom improvement. However, the limited data underscores uncertainty about the peptide's effects and a deficiency in documented safety and effectiveness.

Patients discontinued BPC-157 due to physician advice or adverse effects affecting the neuropsychiatric, dermatologic, and gastrointestinal systems. Experts emphasize that the lack of placebo controls, standardized indications, and outcome assessments makes it impossible to attribute improvements solely to BPC-157, highlighting the need for randomized controlled trials to confirm clinical benefits.